GlaucomaNCT01546740
Prevalence of Glaucoma in the Israeli Arab Population
An observational study of Glaucoma, run by Ziv Hospital at 1 site in Israel.
Trial summary
there is a variety of glaucoma prevalence within different populations. this study examine the prevalence of glaucoma in the Arab population in Israel' as well as the demographic variables and the compliance to treatment in the population. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Glaucoma
- How many people
- 15,000 participants
- Where
- 1 siteIsrael
- Study dates
- Jan 2012to May 2012
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: primary care clinics from 1 Arab city in the center of Israel
Who may be able to join
- Cup-to-disk ratio (CDR) > 0.5 with asymmetry between the eyes
- Intraocular pressure (IOP) > 23 mm Hg
- Damage to the field of vision
- Age- above 20 Yrs. old
Who cannot join
- None
Trial locations and contacts
1 site in 1 country.
Israel1 site, 1 recruiting
- Recruiting
Ziv Medical Center
Safed, 13120
Joseph Pikkel, M.D, +972508434206, pikel.y@ziv.health.gov.il
Otzem Chassid, M.D, +972506266059, otzem.c@ziv.health.gov.il
About this study
Official title: Glaucoma Prevalence in the Israeli Arab Population
there is a variety of glaucoma prevalence within different populations. this study examine the prevalence of glaucoma in the Arab population in Israel' as well as the demographic variables and the compliance to treatment in the population.
Read the detailed description
from Medical records of primary care clinic in the city of Tira. the patients are recruited, all glaucoma patients are above age of 20 years. they must suffer from CDR >= 0.5 with/without asymmetry with the other eye. or they suffer from glaucomatous damage to the visual fields.
- Conditions
- Glaucoma
- Keywords
- Glaucoma, Compliance, Prevalence
- Medical subject headings
- Glaucoma, Patient Compliance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Glaucoma patients | all the ,medical records of patients who were diagnosed with primary open angle glaucoma, closed angle , pseudoexfoliative and neovascular glaucoma. |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2012 (estimated)
- Study startJan 2012
- Primary completionApr 2012 (estimated)
- Study completionMay 2012 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlaucomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Retrospective
- Enrolment
- 15,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ziv Hospital
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Joseph Pikkel, M.D, Principal investigator, Ziv Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01546740
- Sponsor's protocol ID
- ZIV-0060-11
- Status last verified
- Mar 2012
- First submitted
- 1 Mar 2012
- Last updated
- 7 Mar 2012
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 7 Mar 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Glaucoma Prevalence in the Israeli Arab Population
- ClinicalTrials.gov ID
- NCT01546740
- Acronym / sponsor ID
- ZIV-0060-11
- Conditions
- Glaucoma
- Keywords
- Glaucoma, Compliance, Prevalence
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 15,000 participants (estimated)
- Lead sponsor
- Ziv HospitalOther government
- Study start
- Jan 2012
- Primary completion
- Apr 2012 (estimated)
- Study completion
- May 2012 (estimated)
- First posted
- 7 Mar 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
there is a variety of glaucoma prevalence within different populations. this study examine the prevalence of glaucoma in the Arab population in Israel' as well as the demographic variables and the compliance to treatment in the population.
Detailed description
from Medical records of primary care clinic in the city of Tira. the patients are recruited, all glaucoma patients are above age of 20 years. they must suffer from CDR >= 0.5 with/without asymmetry with the other eye. or they suffer from glaucomatous damage to the visual fields.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Glaucoma patients | – | –all the ,medical records of patients who were diagnosed with primary open angle glaucoma, closed angle , pseudoexfoliative and neovascular glaucoma. |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- primary care clinics from 1 Arab city in the center of Israel
Key inclusion criteria (4 listed)
- Cup-to-disk ratio (CDR) > 0.5 with asymmetry between the eyes
- Intraocular pressure (IOP) > 23 mm Hg
- Damage to the field of vision
- Age- above 20 Yrs. old
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Mar 2012.
Related trials for Glaucoma
Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Not yet recruiting
AI-Assisted vs Conventional Teleglaucoma Referral
Glaucoma
Recruiting
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Recruiting
Automated Applanation Tonometry - Updated
Glaucoma, Glaucoma, Suspect
RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Joseph Pikkel, M.D principal investigator
Ziv Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Glaucoma, run by Ziv Hospital at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 7 Mar 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Joseph Pikkel, M.D (+972508434206, pikel.y@ziv.health.gov.il), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2012.